Spiracur Expands Global Reach With The Release Of New International Clinical Data And The Introduction Of The SNaP Plus Therapy System

SUNNYVALE, CA--(Marketwired - June 02, 2015) -

Spiracur today announced that results from new European clinical studies of its SNaP® Therapy System confirm the positive impact of its device on wound healing and patient quality of life reported in previous multicenter Randomized Controlled Trial (RCT) findings. The positive response to this new data, presented in London at the European Wound Management Association (EWMA) conference May 13-15, demonstrates the global demand for more effective wound healing therapies that also provide a high level of patient satisfaction and significant healthcare cost savings.

Two studies, conducted in Cardiff, United Kingdom, and in Pisa, Italy, both met similar primary and secondary clinical objectives. The clinical objectives of both studies were to assess the efficacy of SNaP Therapy in promoting healing of chronic wounds, and the impact of an ultraportable negative pressure wound therapy (NPWT) device on patients’ quality of life. Data from a previous RCT(1) comparing the SNaP Therapy System to the KCI V.A.C.® System demonstrated non-inferiority in wound healing outcomes as well as a significant improvement in quality of life when using the lightweight, ultraportable SNaP Therapy System. Data from the new studies corroborate these findings.

Results from a third clinical study, conducted at a large teaching hospital in Melbourne, Australia, were also presented at the EWMA meeting in London. The data from the Australian study not only further confirmed the clinical efficacy and improved quality of life of the SNaP Therapy System, but also reported a 30 percent decrease in cost as compared to an alternative NPWT.

“The clinical effectiveness of the SNaP Therapy System, combined with its small size and portability, provides patients suffering from chronic wounds a solution that not only heals their wounds but also increases their comfort and mobility, thereby reducing social isolation and improving their quality of life,” said William H. Tettelbach, M.D., FACP, CWS., medical director of Wound Care & Ostomy for Intermountain Healthcare, Salt Lake City, Utah. “As a result, patient compliance to treatment improves and so does wound healing.”

Alongside the presentation of these new data, Spiracur introduced the SNaP Plus Therapy System to international markets. The SNaP Plus Therapy System combines a larger exudate capacity with the clinical advantages of SNaP technology including reduced dressing application time; off-the-shelf availability for wound management efficiency; single-use for reduced risk of hospital acquired infections and cross contamination; and a documented improvement in patient satisfaction.

“We are extremely pleased at the enthusiastic reception of the SNaP Therapy products from the international scientific community,” said Chris Fashek, president and chief executive officer for Spiracur. “There exists a worldwide need for a cost-effective NPWT solution that has been proven as equal or superior to other NPWT therapies in efficacy, is preferred by patients, and is easier to use for the clinician. Our patented technology is uniquely positioned to change the way hospitals and providers deliver NPWT to patients with a single patient product that is disposed of after use, reducing the risk of infection and cross contamination.”

Spiracur will next showcase their range of NPWT products at the Wound, Ostomy, and Continence Nurses Society (WOCN) conference in San Antonio, Texas. Demonstrations of the SNaP Plus Therapy System are scheduled in Spiracur’s booth, #271, Sunday-Tuesday, June 7-9, 2015 during exhibit hours.

About Spiracur Inc.
Spiracur Inc., headquartered in Sunnyvale, California, is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford University Biodesign Innovation Program in 2007. Its first product, the SNaP Therapy System for the treatment of chronic and acute wounds, is the result of patient and clinician feedback that traditional negative pressure wound therapies were too cumbersome. The company’s ciSNaP® Closed Incision System with proprietary controlled tension relief is designed to improve healing of high-risk surgical incisions. Both devices have received 510(k) clearance from the U.S. Food & Drug Administration (FDA) and have received CE Mark approval. Spiracur’s proprietary mechanically powered technology does not require batteries or electricity to operate. For more information, please visit http://spiracur.com.

Spiracur, Spiracur logo, SNaP, Smart Negative Pressure, and ciSNaP are registered trademarks of Spiracur Inc.
VAC is a registered trademark of Kinetic Concepts, Inc.

(1) Armstrong DG, Marston WA, Reyzelman AM, Kirsner RS, Comparative effectiveness of mechanically and electrically powered negative pressure wound therapy devices: a multicenter randomized controlled trial, Wound Repair Regen. 2012 May-Jun; 20(3):332-41. doi: 10.1111/j.1524-475X.2012.00780.x.